Alexion lines up $40M upfront deal with Halozyme to develop a better, easier next-gen followup to Soliris
The recent FDA approval for a revised version of Rituxan and human hyaluronidase enzyme (rHuPH20) as an easy injection has pointed Halozyme to a string of collaborations to do the same for a lineup of major drugs on the market. This morning, the biotech’s hot streak continued with a $40 million upfront pact with Alexion, which wants the delivery tech to turn its next-gen PNH therapy ALXN-1210 into a subcutaneous injectable.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
